MedPharm, Tergus Pharma Join Forces
The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.
MedPharm, Ltd. and Tergus Pharma, have decided to combine their efforts. Together, they are forming a topical and transepithelial contract development and manufacturing organization (CDMO) that will function under the MedPharm name.1
The end result is a CDMO that offers end-to contract services—including early phase research, formulation development, and in vitro testing—while providing clinical trial manufacturing and commercial production services in topical and transepithelial pharma space. There has also been an emphasis on merging each company’s strengths into one integrated organization.
More specifically, the company’s 100,000 square-foot good manufacturing practice (GMP) manufacturing facility in Durham, NC2 will be home to the development and manufacture of hormone-based and highly potent drugs.
“This strategic partnership is an exciting opportunity to deliver extensive pharmaceutical product development resources fueled by a robust team of scientific experts while leveraging our cutting-edge topical GMP facility to seamlessly meet our customers’ commercial production needs,” said Michael Kane, the Tergus Pharma CEO and who has been appointed CEO of MedPharm.
“With locations in both the United Kingdom and the United States, we are well positioned to provide exceptional support to our existing and prospective pharmaceutical clients.”
Patrick Walsh, MedPharm’s executive chairman, added that “Pharma clients have been seeking a reliable, integrated service offering for their ophthalmic, topical and transdermal development and manufacturing projects. This merger creates an immediate option with two organizations already well-positioned in the industry.”
The aforementioned GMP plant was officially unveiled back in May 2021, including speeches that were made North Carolina Gov. Roy Cooper, North Carolina Attorney General Josh Stein, NC Biotech Center president & CEO Doug Edgeton, and was also attended by Tergus Pharma executives, its board of directors, and other individuals.
“This event marks a significant turning point for us,” noted Dr. Vijendra Nalamothu, a former Tergus chairman and CEO. “And the growth spurred on by this facility will create new jobs and business opportunities for the counties of Durham, Wake, and the state of North Carolina. We are proud to be a part of the pharmaceutical success story here in the Triangle area of North Carolina.”
References
1. MedPharm, Ltd. and Tergus Pharma Merger Forms Topical and Transepithelial CDMO Leader. MedPharm. July 8, 2024. Accessed July 9, 2024. https://www.medpharm.com/medpharm-tergus-merger/
2. Tergus Pharma Officially Opens New Headquarters. Tergus Pharma. July 8, 2024. Accessed July 9, 2024. https://www.terguspharma.com/prominent-cdmo-tergus-pharma-officially-opens-new-headquarters/
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
